AbbVie Inc. (ABBV)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 12:33 UTC · Figures derived from the full chain (1,326 contracts, 15 expirations) · IV own-history percentile appears after 60 recorded days (28 so far)
Expected move · Nov 20, 2026 (32 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±7.4% (range 263.84–306.14) by Nov 20, 2026. ATM straddle: 21.15 @ strike 280 · ATM IV: 29.3%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 256.49 | -10% | 87.9% | 12.1% |
| 270.74 | -5% | 70.8% | 29.2% |
| 284.99 | +0% | 48.3% | 51.7% |
| 299.24 | +5% | 27.2% | 72.8% |
| 313.49 | +10% | 12.7% | 87.3% |
Model-estimated probabilities of finishing above/below each level at expiration: estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Nov 20, 2026 · lognormal model with zero drift: an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Oct 23, 2026 | 4 | ±3.1% | 28.0% | 7,951 |
| Oct 30, 2026 | 11 | ±5.7% | 36.4% | 4,646 |
| Nov 06, 2026 | 18 | ±6.6% | 34.3% | 2,408 |
| Nov 13, 2026 | 25 | ±6.9% | 31.0% | 2,832 |
| Nov 20, 2026 | 32 | ±7.4% | 29.3% | 37.9K |
| Nov 27, 2026 | 39 | ±8.1% | 29.8% | 1,170 |
| Dec 18, 2026 | 60 | ±9.8% | 29.2% | 50.1K |
| Jan 15, 2027 | 88 | ±11.4% | 27.8% | 61.8K |
| Feb 19, 2027 | 123 | ±13.8% | 29.5% | 11.6K |
| Mar 19, 2027 | 151 | ±15.3% | 29.4% | 22.9K |
Open interest by strike · Nov 20
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 300 C · 17.4K290 C · 13.4K230 P · 9,484280 C · 6,811240 P · 5,403
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Daily closes; Financial Modeling Prep.
Track record
Full history →Of 93 recorded snapshot-versus-outcome comparisons so far, the close landed inside the expected range 69.9% of the time.
Past earnings reactions
Avg |reaction| 5.1% · median 5.1% (20 reports). Two-session close-to-close window; definition
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatm
Healthcare · Drug Manufacturers - General · NYSE · Profile: Financial Modeling Prep
Related securities · Healthcare
MRNA · IV 110.6%HIMS · IV 89.0%PFE · IV —JNJ · IV 24.5%UNH · IV 28.8%MRK · IV 36.9%